A Study Evaluating the Safety and Efficacy of LentiGlobin BB305 Drug Product in β-Thalassemia Major (Also Referred to as Transfusion-dependent β-Thalassemia [TDT]) and Sickle Cell Disease

Completed

Plain-English translation of NCT02151526 on ClinicalTrials.gov ↗ · Source last updated April 2022 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

Trial locations(1 site)

France

Paris